Contineum Therapeutics, Inc. Class A Common Stock
Symbol: CTNM (NASDAQ)
11.08
▲ (3.02%) 0.325
Company Description:
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Key Stats
- Today's Open: $10.8
- Today's High: $11.495
- Today's Low: $10.785
- Today's Volume: 88.61K
- Yesterday Close: $10.75
- Yesterday High: $11.56
- Yesterday Low: $10.65
- Yesterday Volume: 86.39K
- Last Min Volume: 80
- Last Min High: $11.075
- Last Min Low: $11.075
- Last Min VWAP: $11.075
Company Profile
- Name: Contineum Therapeutics, Inc. Class A Common Stock
- Website: https://www.contineum-tx.com
- Listed Date: 2024-04-05
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001855175
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $301.45M
- Round Lot: 100
- Outstanding Shares: 28.04M
- Asset Type: CS
RECENT FILINGS FOR CTNM
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-18 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-05 | 10-Q | View |
| 2025-08-05 | 8-K | View |
| 2025-08-05 | SCHEDULE 13G/A | View |
| 2025-07-25 | SCHEDULE 13G | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 8-K | View |
| 2025-05-23 | EFFECT | View |
| 2025-05-21 | CORRESP | View |
| 2025-05-20 | UPLOAD | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | S-8 | View |
| 2025-05-14 | 8-K | View |
Latest News on CTNM